Contact Us
CDMO SERVICES
SPECIALIZED MODALITIES
Antibody-Drug Conjugate

Antibody-Drug Conjugate

Mycenax collaborates to provide a comprehensive, one-stop Antibody-Drug Conjugate (ADC) CDMO services, covering the development and production of antibodies, linkers-payloads, and ADCs. These integrated services span from candidate ADC selection and process development to GMP manufacturing.

 

Leveraging the ConjuMX™ Toolbox, we offer a variety of conjugation methods and optimized processes to accelerate and shorten the timeline for new drug development. This platform is also well-suited for the development needs of novel conjugated drugs.

  

 

 

 
 

One-stop CDMO Services to Accelerate Drug Development

  
   
 

Mycenax offers end-to-end solutions spanning from antibody cell line development, linker/drug chemical synthesis to conjugation processes. We provide flexible, stage-specific services tailored to client needs, integrating small-scale experiments through commercial production. This significantly reduces coordination costs while ensuring stable supply of antibodies and linker-payloads. Our optimized, validated processes enable seamless GMP-scale manufacturing readiness.
 
 

 
 
         
 

 

Small-Scale ADC Production: 2 Week+ Turnaround

We provide Small-Scale Preparation and Basic Analysis in 2 weeks. Get the insights you need to move your early development forward.

  
       
       
 

 

In-Process Control (IPC): Achieving Quality Consistency Across Batches/Production Scales

Mycenax’s real-time IPC monitors critical processes and enables regulatory-compliant adjustments, minimizing variability and ensuring consistent quality across batches and scales. This approach supports scale-independent quality—key to precision biomanufacturing of high-value therapeutics.

 
         
 
 

ConjuMX™ Toolbox: Diverse Expertise for Customized Solutions
 
 

The ConjuMX™ Toolbox enables rapid screening of diverse linker-payload combinations and conjugation technologies during early development. It facilitates rapid generation of ADC samples for feasibility studies and analysis.

Leveraging our ConjuMX™ Toolbox, we bring expertise from over 25 ADCs, achieving GMP-grade 50L scale production. Our innovative pipeline includes advancements in bispecific ADCs (BsADCs), trispecific ADCs (TsADCs), and dual-payload ADCs.
 

 
 

Next-generation ADCs: Proprietary Multi-Arm Linker Technology 
 
 

Mycenax has effectively applied its proprietary Multi-Arm Linker technology in ADC development, creating new opportunities and enhanced value for next-generation ADC. This advanced linker design significantly boosts drug-loading capacity, utilizing the synergistic or additive effects of dual payloads to address tumor heterogeneity and overcome drug resistance. As a result, Mycenax’s technology enables more effective and targeted cancer therapies.
 
 

 

 

Our Strategic ADC Partner
 
 
   

KriSan offers small molecule drugs, linkers, payloads, and GMP production for ADC drugs for Mycenax’s global Antibody-Drug Conjugates CDMO business.

Mycenax and KriSan announce a collaboration to strengthen their one-stop service chain for ADC. 

Press release

  

 

 

 

 

 

 

 

 

 

     

 

Mycenax collaborates to provide a comprehensive, one-stop Antibody-Drug Conjugate (ADC) CDMO services, covering the development and production of antibodies, linkers-payloads, and ADCs. These integrated services span from candidate ADC selection and process development to GMP manufacturing.

 

Leveraging the ConjuMX™ Toolbox, we offer a variety of conjugation methods and optimized processes to accelerate and shorten the timeline for new drug development. This platform is also well-suited for the development needs of novel conjugated drugs.
   

 

 
 

One-stop CDMO Services to Accelerate Drug Development

  
   
 

Mycenax offers end-to-end solutions spanning from antibody cell line development, linker/drug chemical synthesis to conjugation processes. We provide flexible, stage-specific services tailored to client needs, integrating small-scale experiments through commercial production. This significantly reduces coordination costs while ensuring stable supply of antibodies and linker-payloads. Our optimized, validated processes enable seamless GMP-scale manufacturing readiness.
 
 

 
         
 

 

Small-Scale ADC Production: 2 Week+ Turnaround

We provide Small-Scale Preparation and Basic Analysis in 2 weeks. Get the insights you need to move your early development forward.

  
       
       
   

In-Process Control (IPC): Achieving Quality Consistency Across Batches/Production Scales

Mycenax’s real-time IPC monitors critical processes and enables regulatory-compliant adjustments, minimizing variability and ensuring consistent quality across batches and scales. This approach supports scale-independent quality—key to precision biomanufacturing of high-value therapeutics.

  
         
 
 

ConjuMX™ Toolbox:

Diverse Expertise for Customized Solutions
 
 

The ConjuMX™ Toolbox enables rapid screening of diverse linker-payload combinations and conjugation technologies during early development. It facilitates rapid generation of ADC samples for feasibility studies and analysis.

Leveraging our ConjuMX™ Toolbox, we bring expertise from over 25 ADCs, achieving GMP-grade 50L scale production. Our innovative pipeline includes advancements in bispecific ADCs (BsADCs), trispecific ADCs (TsADCs), and dual-payload ADCs.
 

 
 

Next-generation ADCs: 

Proprietary Multi-Arm Linker Technology 
 
 

Mycenax has effectively applied its proprietary Multi-Arm Linker technology in ADC development, creating new opportunities and enhanced value for next-generation ADC. This advanced linker design significantly boosts drug-loading capacity, utilizing the synergistic or additive effects of dual payloads to address tumor heterogeneity and overcome drug resistance. As a result, Mycenax’s technology enables more effective and targeted cancer therapies.
 
 

 
 

Our Strategic ADC Partner
 
 

 
 
 

KriSan offers small molecule drugs, linkers, payloads, and GMP production for ADC drugs for Mycenax’s global Antibody-Drug Conjugates CDMO business.

Mycenax and KriSan announce a collaboration to strengthen their one-stop service chain for ADC. 

Press release
 

 

 

 

聯絡我們 Contact Us
確認送出 SEND
GO TOP